Travere Therapeutics, Inc.

Travere Therapeutics announced that Dr. William Rote, Chief Research Officer, will retire effective February 17, 2027. Dr. Rote will continue in his role until his retirement date to ensure a smooth transition of responsibilities. His duties are expected to be assumed by Dr. Jula Inrig, the current Chief Medical Officer, who will also be named Executive Vice President, Head of Research & Development, effective July 1, 2026. The company also plans to engage Dr. Rote in a consulting arrangement post-retirement.

Travere Therapeutics, Inc. has entered into an exclusive license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. for civorebrutinib, a BTK inhibitor. Under the agreement, Travere gains exclusive rights to develop and commercialize the drug in all countries outside of China and certain East and Southeast Asian countries. Travere will make an upfront payment of $112.5 million and Everest is eligible for up to $1.03 billion in milestone payments, plus tiered royalties on net sales.

Travere Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares authorized for issuance by 3,000,000. Additionally, stockholders elected ten directors, provided advisory approval for named executive officer compensation, indicated a preference for annual advisory votes on executive compensation, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026.

Travere Therapeutics, Inc. completed its registered public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032. This amount includes the full exercise of the underwriters' $50.0 million over-allotment option. Approximately $350.9 million of the net proceeds will be used to repurchase $221.4 million of its outstanding 2.25% senior convertible notes due 2029, with the remainder allocated for general corporate purposes. The new notes mature on May 15, 2032, bear 0.50% annual interest, and have an initial conversion price of approximately $64.90 per share.

Travere Therapeutics reported increased revenue and a reduced net loss for the first quarter of 2026. The company also announced the full FDA approval of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) on April 13, 2026, making it the first and only approved medicine for this condition. Additionally, Travere restarted enrollment for its pivotal Phase 3 HARMONY Study for pegtibatinase in Q1 2026, following a voluntary pause to address manufacturing scale-up improvements. The company also reclassified royalty expense for better financial presentation.

Travere Therapeutics reported its first quarter 2026 financial results, highlighted by the FDA approval of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS), significantly expanding its addressable patient population. The company achieved record U.S. net product sales of $124.5 million, an increase from $75.9 million in the prior year, with FILSPARI sales growing 88% to $105.2 million. Despite a GAAP net loss of $37.1 million, Travere reported a non-GAAP adjusted net income of $4.1 million and advanced its pegtibatinase Phase 3 HARMONY study with the first new patient dosed.

Travere Therapeutics announced that the FDA has approved FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks FILSPARI as the first and only FDA-approved medicine for FSGS, expanding its use beyond IgA nephropathy into a second rare kidney disease. The company estimates an addressable U.S. population of over 30,000 individuals with FSGS who do not have nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria from baseline to Week 108 in the overall study population, compared to 30% for irbesartan.

Travere Therapeutics announced FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks FILSPARI as the first and only FDA-approved medicine for FSGS, expanding its use beyond IgA nephropathy into a second rare kidney disease. The company estimates an addressable U.S. population of over 30,000 individuals for this indication, with the Phase 3 DUPLEX study demonstrating significant proteinuria reduction compared to irbesartan.